Clinical and Biochemical Correlation of Intra-articular Platelet-Rich Plasma and Corticosteroid Using Serum Matrix Metalloproteinase 3 (MMP-3) Levels in Osteoarthritis of Knee

Introduction Osteoarthritis (OA) in humans is an inevitable consequence of ageing and can now be effectively managed with advancements in knowledge and understanding of the disease. The major concern in a patient suffering from this disease is the functional impairment caused by the pain. The goals in the management of OA knee include symptom relief with preservation of joint function. Despite there being a number of studies on the effectiveness of PRP and CS for knee OA, most of them have focused on patient-reported functional outcomes only. Hence, we conducted this study to assess the potential and effectiveness of a single intra-articular injection of PRP and CS in the functional improvement of knee OA patients using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analogue Scale (VAS) and to establish the bio-modulatory effects of intra-articular PRP and CS in knee OA patients by estimating the serum matrix metalloproteinase-3 (MMP-3) levels. Methodology Patients attending the outpatient department with complaints of knee pain were screened. Standing anteroposterior and lateral radiographs of the knees were obtained. Patients with Kellgren and Lawrence (K-L) grades II and III were enrolled in our study. A total of 96 patients were included in the study after fulfilling the inclusion and exclusion criteria. Patients were divided into two groups (PRP and CS) by randomisation. There were 48 each in the PRP and CS groups, out of which nine were lost to follow-up, two from the PRP group and seven from the CS group. A total of 87 patients fulfilling the inclusion criteria were finally enrolled in the study and followed up for nine months after a single intra-articular injection. The biochemical assessment of serum levels of MMP-3 was done at baseline and in the ninth month. Accordingly, patients in the PRP group were injected with freshly prepared PRP (3 ml) within two hours of preparation, whereas those in the CS received 80 mg of methylprednisolone acetate. VAS and WOMAC were measured at baseline, and then in the first, third, sixth, and ninth month post-injection follow-ups. MMP-3 level was estimated before the injection and at the ninth-month post-injection follow-up. Data collected for both groups were analysed and compared with each other. Conclusion PRP is unquestionably a better option than CS in OA of the knee based on boosting functional activity, lowering stiffness, and reducing pain, all three of which are denoted by the WOMAC and VAS scores as the effect of PRP lasts longer than CS injections for the aforesaid issues. We could not find any significant change in levels of MMP3 post PRP and CS injections, which signifies that these two modalities do not have any effect in either preventing cartilage degeneration or promoting cartilage regeneration. Our findings have shown that PRP injections are safe, minimally invasive, and effective treatment modalities for OA knee.

[1]  L. Slovinská,et al.  Effect of Intra-Articular Injection of Platelet-Rich Plasma on the Serum Levels of Osteoarthritic Biomarkers in Patients with Unilateral Knee Osteoarthritis , 2021, Journal of clinical medicine.

[2]  N. Heron,et al.  Intra-articular platelet-rich plasma injections versus intra-articular corticosteroid injections for symptomatic management of knee osteoarthritis: systematic review and meta-analysis , 2021, BMC Musculoskeletal Disorders.

[3]  R. Shivashankar,et al.  Comparison of intra articular autologous platelet-rich plasma with steroids in osteoarthritis knee: Experience from a North Indian tertiary care center , 2020 .

[4]  N. Bharath,et al.  A comparative study of functional outcome of osteoarthritis knee post intraarticular injection of PRP and corticosteroid with minimum six months of follow-up , 2019, National Journal of Clinical Orthopaedics.

[5]  Gregory A. Brown,et al.  The American Academy of Orthopaedic Surgeons evidence-based guideline on: treatment of osteoarthritis of the knee, 2nd edition. , 2013, The Journal of bone and joint surgery. American volume.

[6]  H. Madry,et al.  Non-surgical management of early knee osteoarthritis , 2012, Knee Surgery, Sports Traumatology, Arthroscopy.

[7]  K. Brandt,et al.  Radiographic grading of the severity of knee osteoarthritis: relation of the Kellgren and Lawrence grade to a grade based on joint space narrowing, and correlation with arthroscopic evidence of articular cartilage degeneration. , 2010, Arthritis and rheumatism.

[8]  P Tugwell,et al.  OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. , 2010, Osteoarthritis and cartilage.

[9]  K. Frosch,et al.  Influence of Platelet-Rich Plasma on Chondrogenic Differentiation and Proliferation of Chondrocytes and Mesenchymal Stem Cells , 2008, Cells Tissues Organs.

[10]  Johanne Martel-Pelletier,et al.  Cartilage in normal and osteoarthritis conditions. , 2008, Best practice & research. Clinical rheumatology.

[11]  B. Eppley,et al.  Platelet Rich Plasma: Biology and New Technology , 2005, The Journal of craniofacial surgery.

[12]  Hajime Mishima,et al.  Association of increased expression of macrophage elastase (matrix metalloproteinase 12) with rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[13]  Paquita Nurden,et al.  Autologous platelets as a source of proteins for healing and tissue regeneration , 2003, Thrombosis and Haemostasis.

[14]  N. Bellamy WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire. , 2002, The Journal of rheumatology.

[15]  Y. Okada,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis , 2000, Annals of the rheumatic diseases.

[16]  P. Creamer Intra-articular corticosteroid treatment in osteoarthritis. , 1999, Current opinion in rheumatology.

[17]  M. Østergaard,et al.  Intra-Articular Corticosteroids in Arthritic Disease , 1998, BioDrugs.

[18]  A. Koch,et al.  Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[19]  Martin Underwood,et al.  Osteoarthritis: national clinical guideline for care and management in adults , 2008 .

[20]  H. Benghuzzi,et al.  Cellular effects of platelet rich plasma: a study on HL-60 macrophage-like cells. , 2007, Biomedical sciences instrumentation.